Trial Profile
A Study of the Impact of Adalimumab on Patient-reported Outcomes (PROs) in Canadian Patients Suffering From Moderate-to-severe Ulcerative Colitis (UCanADA)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms UCanADA
- Sponsors AbbVie
- 06 Mar 2020 Status changed from active, no longer recruiting to completed.
- 16 Apr 2019 Planned End Date changed from 31 Dec 2019 to 30 Apr 2020.
- 16 Apr 2019 Planned primary completion date changed from 31 Dec 2019 to 30 Apr 2020.